Insider Selling: CeriBell (NASDAQ:CBLL) CFO Sells $24,750.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 990 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $25.00, for a total value of $24,750.00. Following the transaction, the chief financial officer directly owned 148,121 shares in the company, valued at $3,703,025. This trade represents a 0.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Scott Blumberg also recently made the following trade(s):

• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total value of $838,805.36.

CeriBell Stock Performance

Shares of NASDAQ CBLL traded down $0.58 during mid-day trading on Thursday, reaching $24.31. 262,277 shares of the company were exchanged, compared to its average volume of 469,652. The company’s 50-day simple moving average is $19.43 and its 200-day simple moving average is $19.19. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $933.02 million, a P/E ratio of -13.81 and a beta of 0.81. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $25.33.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The business had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. As a group, research analysts predict that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Canaccord Genuity Group increased their target price on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Barclays raised shares of CeriBell to a “neutral” rating in a research note on Tuesday. Finally, BTIG Research increased their price target on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.40.

Hedge Funds Weigh In On CeriBell

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd lifted its holdings in shares of CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares during the period. Strs Ohio bought a new stake in shares of CeriBell in the 1st quarter valued at about $27,000. CWM LLC increased its stake in shares of CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares during the period. Tower Research Capital LLC TRC raised its position in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in shares of CeriBell during the second quarter worth about $53,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.